| Dr Hareesh Kumar Gundlapalli, MD | |
|
1100 Central Ave Se, Albuquerque, NM 87106-4930 | |
| (505) 724-6124 | |
| Not Available |
| Full Name | Dr Hareesh Kumar Gundlapalli |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 1100 Central Ave Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184903437 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD167542 (Oregon) | Secondary |
| 207R00000X | Internal Medicine | MD2019-0219 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus Santa Rosa Medical Center | San antonio, TX | Hospital |
| Methodist Hospital | San antonio, TX | Hospital |
| Presbyterian Hospital | Albuquerque, NM | Hospital |
| University Of New Mexico Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Texas Pllc | 3476688318 | 951 |
| Presbyterian Healthcare Services | 9234041708 | 1099 |
| Inpatient Progressive Health Of America, Pllc | 5698072320 | 64 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
In this End the Neglect blog post, Linda Diep, communications and grassroots assistant with the Global Network for Neglected Tropical Diseases, discusses how "mapping of Loa Loa Filariasis could help in the innovation of new strategies to eliminate and control onchocerciasis and lymphatic filariasis (LF), according to a recently released article from the open-access journal PLoS Neglected Tropical Diseases."
› Verified 5 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
In this End the Neglect blog post, Linda Diep, communications and grassroots assistant with the Global Network for Neglected Tropical Diseases, discusses how "mapping of Loa Loa Filariasis could help in the innovation of new strategies to eliminate and control onchocerciasis and lymphatic filariasis (LF), according to a recently released article from the open-access journal PLoS Neglected Tropical Diseases."
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20151019001400 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
In this End the Neglect blog post, Linda Diep, communications and grassroots assistant with the Global Network for Neglected Tropical Diseases, discusses how "mapping of Loa Loa Filariasis could help in the innovation of new strategies to eliminate and control onchocerciasis and lymphatic filariasis (LF), according to a recently released article from the open-access journal PLoS Neglected Tropical Diseases."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hareesh Kumar Gundlapalli, MD Po Box 26666, Provider Enrollment, Albuquerque, NM 87125-6666 Ph: (505) 923-6770 | Dr Hareesh Kumar Gundlapalli, MD 1100 Central Ave Se, Albuquerque, NM 87106-4930 Ph: (505) 724-6124 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
In this End the Neglect blog post, Linda Diep, communications and grassroots assistant with the Global Network for Neglected Tropical Diseases, discusses how "mapping of Loa Loa Filariasis could help in the innovation of new strategies to eliminate and control onchocerciasis and lymphatic filariasis (LF), according to a recently released article from the open-access journal PLoS Neglected Tropical Diseases."
› Verified 5 days ago
Dr. Alberto Aguayo Rico, M.D, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |